West Pharmaceutical Services (STU:WPS) Growth Rank: 9 (As of Sep. 22, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:WPS West Pharmaceutical Services Inc STU:WPS
94 GF Score
Price €314.80
GF Value €307.30
! 9 Warning Signs
View Full Analysis

What is West Pharmaceutical Services Growth Rank?

West Pharmaceutical Services STU:WPS -1.75% 94 Growth Rank is 9 as of Sep. 22, 2026, which is at its 10-year median of 9.00. GuruFocus rates STU:WPS with a GF Score™ of 94/100 and a GF Value™ of €307.30. The stock has 9 warning signs investors should review.

West Pharmaceutical Services has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

West Pharmaceutical Services Growth Rank Related Terms

STU:WPS vs MDLN, SOLV, COO: Growth Rank Comparison

For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

West Pharmaceutical Services Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's Growth Rank distribution charts can be found below:

* The bar in red indicates where West Pharmaceutical Services's Growth Rank falls into.


STU:WPS
94GF Score
West Pharmaceutical Services Inc STU:WPS
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
West Pharmaceutical Services (STU:WPS) has a Growth Rank of 9 as of Sep. 22, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on West Pharmaceutical Services and its competitors. This is near median its historical median of 9.00. Over the past decade, West Pharmaceutical Services' Growth Rank has ranged from 4.00 to 10.00.
Is West Pharmaceutical Services' Growth Rank too high?
West Pharmaceutical Services' current Growth Rank of 9 is near median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, West Pharmaceutical Services has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' Growth Rank compare to MDLN and SOLV?
West Pharmaceutical Services' Growth Rank of 9 can be compared against companies in the Medical Devices & Instruments industry. Historically, West Pharmaceutical Services' own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on West Pharmaceutical Services and its competitors. West Pharmaceutical Services's current Growth Rank is 9, which is near median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
West Pharmaceutical Services (STU:WPS) has a current Growth Rank of 9. The stock's GF Value™ is €307.30, compared to a current price of €314.80 — trading 2.4% above its estimated fair value. The current Growth Rank is 9, which is near median its 10-year median of 9.00. West Pharmaceutical Services' overall GF Score™ is 94/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For West Pharmaceutical Services (STU:WPS), the current Growth Rank is 9 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is West Pharmaceutical Services (STU:WPS) Overvalued in 2026?

Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be overvalued. The current stock price of €314.80 is trading 2.4% above its estimated GF Value™ of €307.30.

Key valuation signals for STU:WPS:

  • Growth Rank: 9 (near median its 10-year median of 9.00)
  • GF Value™: €307.30 vs. price of €314.80 (2.4% above fair value)
  • GF Score™: 94/100 with 9 warning signs

No single metric tells the full story. See the STU:WPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

West Pharmaceutical Services Business Description

Address 530 Herman O. West Drive, Exton, PA, USA, 19341-1147
West Pharmaceutical Services Inc. is a Pennsylvania-based supplier to the pharmaceutical, biotechnology, and generic drug industries. The company provides elastomer-based packaging components such as stoppers, seals, and plungers, along with non-glass containment solutions and self-injection devices including auto-injectors and pen injectors. Its products support injectable drugs, including large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. West reports in two segments: proprietary products, which account for the majority of revenue and include its high-value packaging and delivery systems, and contract-manufactured products, which involve manufacturing services for other companies. Customers include pharmaceutical and biotechnology firms worldwide. The company generates a substantial share of revenue from international markets, with the remainder from the United States. Its revenue model centers on selling consumable packaging components and delivery devices tied to ongoing drug production, supplemented by contract manufacturing services.
94GF Score

Get the complete analysis for STU:WPS

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€314.80
Price
€307.30
GF Value